65,437 trials
Hypertension · Emergencies · Asymptomatic Conditions
Primary: Number of Participants Who Died Within 7 Days After Discharge From the Emergency Department — 0; 0 participants
Asthma · Children
Primary: Hospital Admission — 11; 8 participants — p=0.689
Venous Leg Ulcer · Venous Stasis Ulcers
Primary: The Average Percent (%) Change From Baseline in the Target Wound Area in Each Treatment Group Over the Twelve-week Double-blind Treatment Period. — -77.11; -70.15…
Venous Leg Ulcers
Primary: Compare the Treatment Groups for the Proportion of Subjects With Complete Wound Closure Over the 12-Week Treatment Period From Baseline — 129; 126; 82; 84 participants…
Cytomegalovirus Retinitis · HIV Infections
Primary: Survival — 31; 30 participants
Oral Mucositis
Primary: WHO (World Health Organisation) Oral Mucositis Severity Score During 28 Days of Treatment, Intention to Treat Population — 0.63; 0.56 score
Bladder Cancer
Primary: Progression Free Survival — 8.2 months
Surgery · Anesthesia
Primary: Quality of Recovery Score 24 Hours Post Operative — 175; 176 units on a scale — p=0.97
Low Back Pain
Primary: Number of Days on Sick Leave — 9.5; 9.2; 3.6 Days
Periodontal Health · Dental Plaque Accumulation
Primary: Gingival Health — 0.46; 0.18 units on a scale — p=0.015
Aortic Coarctation
Primary: Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening — 55 participants
Parkinson · Tremor
Primary: Unified Parkinsons Disease Rating Scale (UPDRS) Tremor Scale — 0; 8 participants — p=0.0007
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 2; 0 Participants
Multiple Sclerosis
Primary: Measure: Number of Subjects With Adverse Events, Number of Abnormalities in Safety Assessments — 12; 8 participants
Pulmonary Stenosis · Pulmonary Regurgitation · Tetralogy of Fallot
Primary: Successful Repair of Conduit Disruption — 48 participants